Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Canada / NCT06638073
Active, not recruiting Observational

Continuous Connected Patient Care (CCPC), a Pilot Testing a Novel Device for Continuous Vitals Monitoring - Department of Anesthesia at PHC

NCT06638073 · tracked via the Priya Life Science Canada tracker
Sponsor
Medtronic - MITG
Phase
Observational
Started
2025-03-13
Last updated
2026-10-15

Condition(s) studied

Surgical Procedure, UnspecifiedIntensive Care Units (ICUs)

Study summary

To confirm feasibility and accessibility of the CCPC Platform (Oxymotion, Bridge Health Solutions medication adherence software, CloudDX home kit) in two different environments - in hospital and at-home, in patients undergoing non-cardiac surgery.

Eligibility

Sex
ALL
Min age
19 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * 19 years or older * Patients that have undergone a non-cardiac surgery at SPH requiring an inpatient hospital stay * Peri-op patients who are in the Surgical High Acuity Unit (SHAU) and those followed by Anesthesia Perioperative Outreach team on the ward * Living within British Columbia, Canada and in an area that is covered by Bell cellular network Exclusion Criteria: * Patient refusal * Lack of capacity to consent to the study (including having received sedative or general anesthetic within the past 24 hours) * Unable to use (or does not have a caregiver who can help put on) study monitoring device at home * Unable to complete (or does not have a caregiver who can help complete) study questionnaires by electronic (mobile, tablet, or computer), paper, nor phone * No access to cell phone nor landline at home to receive follow-ups * Preoperatively known to be discharged to a nursing home or rehabilitation facility * Known allergic reactions to any part material of study devices

Primary outcome measure(s)

  • Collect patient and clinicians' feedback about the CCPC Platform — From enrollment to the end of follow up at 10 days
    This will be completed via an assessment of the quantitative data on how long and how often patients use this monitoring and what were the reasons that patients took the monitors on and off.
  • Confirm the technical goals of the CCPC platform are met. — From enrollment to the end of follow up at 10 days
    This will be completed by ensuring clinical workflow is met when using the monitoring platform.
  • Collect patient and clinicians' feedback about the CCPC Platform — From enrollment to the end of follow up at 10 days
    This will be completed via an assessment of the Usability questionnaires.
  • Collect patient and clinicians' feedback about the CCPC Platform — From enrollment to the end of follow up at 10 days
    This will be completed by an evaluation of potential harm, adverse events and safety issues.
  • Confirm the technical goals of the CCPC platform are met. — From enrollment to the end of follow up at 10 days
    This will be completed via an assessment of the data flow: does the correct patient vitals information reach the clinicians at the right time?
  • Confirm the technical goals of the CCPC platform are met. — From enrollment to the end of follow up at 10 days
    This will be completed by determining if the CCPC platform provided a holistic view of each patient with vitals, medication, and other collected data.

Trial sites (1)

FacilityCityRegionStatus
Saint Pauls Hospital Vancouver British Columbia

More Medtronic - MITG trials in Canada

Continuous Connected Patient Care (CCPC), a Pilot Testing a Novel Device for Continuous Vitals Monitoring - Older Adults Department PHC Recruiting
Randomized Trial of UI-EWD vs. Conventional Endoscopic Therapy for Nonvariceal Upper Gastrointestinal Bleeding Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06638073 on ClinicalTrials.gov ↗ ← All trials in Canada